2026-10-28 09:03:27 UTC#527160newconfirmednews
CSPC Pharmaceutical Group stock news
CSPC Pharmaceutical Group stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-23 01:21:44 UTC#503772newconfirmednews
CSPC Pharmaceutical receives NMPA drug registration certificate for Batoclimab (Enlida) injection
reutersimportance 0.50trust 0.90CSPC Pharmaceutical Group Limited +0.60Batoclimab +0.60National Medical Products Administration +0.50
2026-10-22 16:35:26 UTC#501351newconfirmednews
CSPC Pharmaceutical initiates Phase III trial of SYS6043 for triple-negative breast cancer in China
2026-10-20 10:24:04 UTC#485672newconfirmedpress release
CSPC Pharmaceutical initiates Phase I clinical trial for dry eye disease drug SYH2083 in China
2026-10-15 10:24:38 UTC#464812newconfirmedpress release
CSPC Pharmaceutical Group receives NMPA approval for SYS6062 clinical trial in China
reutersimportance 0.40trust 0.90CSPC Pharmaceutical Group Limited +0.30SYS6062 +0.30National Medical Products Administration +0.20+1 entities
2026-09-29 10:21:26 UTC#383243newconfirmednews
CSPC Pharmaceutical initiates Phase IB trial of JMT206 injection for weight management in China
reutersimportance 0.40trust 0.90CSPC Pharmaceutical Group Limited +0.30JMT206 +0.30Semaglutide +0.10
2026-09-24 09:04:41 UTC#361089newconfirmednews
CSPC Pharmaceutical initiates Phase III clinical trial of HB1801 for advanced breast cancer in China
2026-09-10 05:48:00 UTC#289718newconfirmednews
DBS Group Research resumes coverage of CSPC Pharmaceutical (1093.HK) with Buy rating
2026-09-01 15:56:16 UTC#250531newconfirmednews
CSPC Pharmaceutical initiates Phase I clinical trial for depression drug SYH2056 in China
2026-08-31 15:29:02 UTC#243649newconfirmednews
CSPC Pharmaceutical initiates Phase I clinical trial for weight management drug SYH2092 in China
2026-08-26 10:32:46 UTC#222343newconfirmednews
CSPC Pharmaceutical's SYS6010 meets primary endpoint of progression-free survival in Phase III SYNSTAR-01 study
reutersimportance 0.60trust 0.90CSPC Pharmaceutical Group Limited +0.60SYS6010 +0.60SYNSTAR-01 +0.60
2026-08-25 14:07:51 UTC#217982newconfirmednews
CSPC Pharmaceutical's SYS6057 RSV vaccine receives US clinical trial approval
reutersimportance 0.50trust 0.90CSPC Pharmaceutical Group Limited +0.40SYS6057 +0.40National Medical Products Administration +0.20+1 entities
2026-08-23 23:13:57 UTC#209752newconfirmednews
CSPC Pharmaceutical H1 profit rises 139% to RMB18.6B; NMPA accepts NDAs for KN026 and HB1801
tradingviewimportance 0.40trust 0.70CSPC Pharmaceutical Group Limited +0.60National Medical Products Administration +0.40KN026 +0.30+1 entities
2026-08-20 04:31:00 UTC#198684duplicateconfirmednews
CSPC Pharmaceutical 1H revenue growth driven by higher license fees and finished drug sales
2026-08-20 04:30:07 UTC#198685duplicateconfirmednews
CSPC Pharmaceutical H1 2026 revenue rises 40% on finished drug growth, net profit up 139%
2026-08-20 04:30:00 UTC#198687updateconfirmeddata release
CSPC Pharmaceutical (1093.HK) 1H 2026 Revenue CNY18.59B vs CNY13.27B Year-Over-Year
2026-08-20 04:30:00 UTC#198686updateconfirmeddata release
CSPC Pharmaceutical 1H 2026 Net Profit CNY6.09B vs CNY2.55B Year-Over-Year
2026-08-20 04:22:20 UTC#198660newconfirmednews
CSPC Pharmaceutical Group H1 2026 Revenue Up 40.1% to RMB18.6B, Net Profit Jumps 139.2%
2026-08-18 15:22:01 UTC#190504newconfirmednews
CSPC Pharmaceutical NMPA NDA Acceptance for KN026 and HB1801 Combination in Advanced Breast Cancer
reutersimportance 0.40trust 0.80CSPC Pharmaceutical Group Limited +0.40National Medical Products Administration +0.30KN026 +0.40+1 entities
2026-08-16 23:13:34 UTC#182385newconfirmednews
CSPC Pharmaceutical receives $30M from AstraZeneca and initiates Phase I trial for SYS6063 in China
tradingviewimportance 0.30trust 0.50CSPC Pharmaceutical Group Limited +0.50AstraZeneca PLC +0.30SYS6063 +0.40+1 entities